147249-33-0 Usage
Description
Aspalatone is a synthetic chemical compound recognized for its bioactive antioxidant potential. It is known to scavenge free radicals and reduce oxidative stress in the body, which may contribute to its health-promoting effects. Aspalatone is a promising compound with diverse potential applications in health and wellness.
Uses
Used in Cosmetic and Skincare Industry:
Aspalatone is used as an antioxidant in the cosmetic and skincare industry for its potential to protect the skin from environmental stressors and reduce signs of aging.
Used in Neurological Disorders Treatment:
Aspalatone is used as a therapeutic agent in the treatment of neurological disorders due to its potential neuroprotective effects.
Used in Cardiovascular Diseases Treatment:
Aspalatone is used as a therapeutic agent in the treatment of cardiovascular diseases, potentially contributing to improved heart health through its antioxidant properties.
Used in Inflammatory Conditions Treatment:
Aspalatone is used as a therapeutic agent in the treatment of inflammatory conditions, possibly aiding in the reduction of inflammation through its antioxidant mechanisms.
Check Digit Verification of cas no
The CAS Registry Mumber 147249-33-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,7,2,4 and 9 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 147249-33:
(8*1)+(7*4)+(6*7)+(5*2)+(4*4)+(3*9)+(2*3)+(1*3)=140
140 % 10 = 0
So 147249-33-0 is a valid CAS Registry Number.
InChI:InChI=1/C15H12O6/c1-9-14(12(17)7-8-19-9)21-15(18)11-5-3-4-6-13(11)20-10(2)16/h3-8H,1-2H3
147249-33-0Relevant articles and documents
Synthesis and antiplatelet effects of the new antithrombotic agent aspalatone with low ulcerogenicity
Han,Suh,Yang,Park,Kang,Kim
, p. 1122 - 1126 (2007/10/02)
A new compound, aspalatone (acetylsalicylic acid maltol ester), was synthesized by esterification of acetylsalicylic acid (ASA) and maltol, an antioxidant, and studied for its bleeding time prolongation effect in rats for its antiplatelet aggregation activity in vitro and ex vitro in rats, and for its antithrombotic activity in vivo using the mouse thromboembolism test. Aspalatone treatment (15 mg/kg p.o.) for 10 days prolonged bleeding time by 57% (p 50 of 1.8 x 10-4 mol/l, but, similar to ASA, did not significantly inhibit ADP-induced aggregation. The ability of oral aspalatone to inhibit platelet aggregation in rats ex vivo was compared with other reference antiplatelet drugs. Relative potency was ASA > dipyridamole ? aspalatone > ticlopidine. A single dose of asplatone potently prevented death due to collagen-induced platelet aggregation in mice in vivo with ED50 value of 32 mg/kg p.o., but failed to prevent death due to ADP-induced platelet aggregation. When given for 10 days, aspalatone prevented collagen-induced death by 90% (p 50 values for malondialdehyde degeneration in vitro were 1.1 x 10-4 mol/l and 8.4 x 10-5 mol/l, respectively. These results suggest that aspalatone might be a potential antithrombotic agent with low ulcerogenicity.